Last updated: September 20, 2026
Bevacizumab-bvzr, marketed by Pfizer as Zirabev, is a U.S.-approved biosimilar to Genentech’s Avastin. Its commercial position is driven by hospital and oncology-provider purchasing, payer substitution, Medicare reimbursement, and competition from other bevacizumab biosimilars. Pfizer does not publicly report Zirabev revenue as a separate line item, so the product’s financial trajectory must be assessed through biosimilar portfolio disclosures, market access, price erosion, and market-share conditions.
Zirabev has no conventional small-molecule patent cliff. The reference product’s U.S. biologic exclusivity expired before Zirabev’s approval, while market entry depended on biosimilar approval, patent litigation, and commercial contracting. Its principal risks are price compression, rapid share fragmentation, and additional bevacizumab biosimilars rather than loss of exclusivity on a single Orange Book-listed patent.
What is bevacizumab-bvzr and who markets Zirabev?
Bevacizumab-bvzr is a recombinant monoclonal antibody biosimilar to bevacizumab, the active ingredient in Avastin. Pfizer markets it in the United States under the brand name Zirabev. The product is supplied for intravenous infusion and is used in oncology indications aligned with the approved Avastin reference-product labeling.
FDA regulatory status
The FDA approved Zirabev on June 27, 2019, under the Biologics Price Competition and Innovation Act biosimilar pathway. The approval covered the following Avastin-referenced indications:
| Therapeutic area |
U.S. status |
| Metastatic colorectal cancer |
Approved |
| Metastatic breast cancer |
Approved for specified regimens |
| Non-small-cell lung cancer |
Approved for specified regimens |
| Glioblastoma |
Approved |
| Metastatic renal cell carcinoma |
Approved with interferon alfa |
| Persistent, recurrent, or metastatic cervical cancer |
Approved |
| Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Approved for specified settings |
The FDA determined that Zirabev is biosimilar to Avastin. The product was not initially designated interchangeable with Avastin. Biosimilarity permits approval based on analytical, pharmacokinetic, immunogenicity, and clinical comparability evidence, but it does not automatically create pharmacy-level substitution rights.
Pfizer’s European product is also marketed as Zirabev. The European Medicines Agency authorized it in 2019 under the centralized biosimilar framework. European uptake has generally been more dependent on national tenders and hospital procurement than on U.S.-style physician prescribing.
When did bevacizumab-bvzr lose exclusivity?
Zirabev did not lose a separate period of reference-product exclusivity. It entered after Avastin’s 12-year U.S. biologic exclusivity period had expired.
| Event |
Date |
| Avastin U.S. approval |
2004 |
| Expiration of 12-year reference biologic exclusivity |
2016-2017 period, depending on statutory calculation and approval-date treatment |
| FDA approval of Mvasi, first U.S. bevacizumab biosimilar |
September 2017 |
| FDA approval of Zirabev |
June 27, 2019 |
| U.S. commercial launch of Zirabev |
January 2020 |
| FDA approval of additional U.S. bevacizumab biosimilars |
2022 onward |
The commercial exclusivity window for Zirabev is therefore based on Pfizer’s launch position and contracting strength, not on a standalone 12-year period. Zirabev’s market protection weakened as additional bevacizumab biosimilars entered the U.S. market.
What patents protect bevacizumab-bvzr and Avastin?
Bevacizumab-bvzr is a biologic and is not listed in the FDA Orange Book in the same manner as a small-molecule drug. The relevant U.S. patent and exclusivity information is found through the FDA Purple Book, patent litigation records, and the BPCIA patent-exchange process.
Avastin’s historical patent estate covered the bevacizumab molecule, antibody production, compositions, and related technologies. Patent protection was more relevant to the timing of biosimilar entry than to Zirabev’s post-launch commercial trajectory.
Orange Book and Purple Book status
| Issue |
Zirabev status |
| Orange Book listing |
Not the principal listing system for this biologic |
| Purple Book listing |
Relevant |
| Biosimilar designation |
Yes |
| Interchangeable designation |
Not listed as interchangeable at original approval |
| Reference product |
Avastin |
| Patent-certification framework |
BPCIA, not conventional ANDA Paragraph IV certification |
A conventional Paragraph IV filing is associated with an abbreviated new drug application for small-molecule products. Biosimilar applicants instead exchange patent information with the reference-product sponsor under the BPCIA. Patent disputes can proceed under the BPCIA and related federal litigation, but the process is not identical to an ANDA Paragraph IV challenge.
What patent litigation affects bevacizumab-bvzr?
Zirabev’s entry followed the first wave of U.S. bevacizumab biosimilar litigation and settlement activity. The most important commercial question was whether Pfizer could launch without infringing enforceable Genentech patents and whether any settlement restricted the launch date.
Publicly available regulatory and company materials identify Zirabev as an approved Avastin biosimilar, but Pfizer does not report a product-specific patent term that would establish a future Zirabev expiration date. The product does not have a standard Orange Book patent-expiration date comparable to a tablet or capsule marketed under an NDA.
The relevant legal structure is:
- Genentech and Roche held the reference-product rights and related patent interests.
- Pfizer pursued U.S. approval through the biosimilar pathway.
- Patent disputes were assessed through BPCIA procedures and federal litigation.
- Commercial launch occurred in January 2020.
- Subsequent market entry by competing biosimilars reduced the economic value of any remaining patent-related protection.
Settlement agreements
Biosimilar settlements can establish permitted launch dates, geographic restrictions, or other commercial terms. Public sources do not provide a standalone, product-level Zirabev settlement framework that supports a single later patent-loss date. The observable market fact is that Zirabev launched in the United States in 2020 and faced multiple competing bevacizumab biosimilars thereafter.
How many patents cover bevacizumab-bvzr?
No reliable public count of patents covering Zirabev can be reduced to a single commercially meaningful number. Biologic patent estates include composition, sequence, formulation, cell-line, manufacturing, purification, and use claims. Some claims may cover the reference product, while others may be designed around by a biosimilar manufacturer.
For investment and licensing analysis, the more relevant distinction is between:
- patents covering the Avastin reference product;
- patents potentially applicable to Zirabev’s manufacturing process;
- patents covering oncology methods of use;
- patents covering formulations, containers, or administration systems; and
- patents owned or licensed by Pfizer for its own production platform.
What formulations are protected?
Zirabev is supplied as a sterile intravenous solution in single-dose vials. Formulation and container-closure patents can create manufacturing barriers even when the core antibody claims have expired. These rights generally have less effect on market entry than composition or manufacturing patents because biosimilar developers can use alternative formulations and production processes, subject to FDA comparability requirements.
The main technical barriers are process consistency, glycosylation control, aggregation management, viral clearance, analytical characterization, and scale-up. These are difficult to replicate but are not equivalent to patent exclusivity.
Which companies are challenging or competing with Zirabev?
The U.S. bevacizumab market has shifted from a reference-product versus one-biosimilar structure to a multi-biosimilar market.
| Product |
Active ingredient |
Sponsor |
U.S. regulatory position |
| Avastin |
Bevacizumab |
Genentech/Roche |
Reference biologic |
| Mvasi |
Bevacizumab-awwb |
Amgen |
First U.S. bevacizumab biosimilar |
| Zirabev |
Bevacizumab-bvzr |
Pfizer |
U.S. biosimilar |
| Alymsys |
Bevacizumab-maly |
mAbxience, commercialized in the U.S. by Fresenius Kabi |
U.S. biosimilar |
| Vegzelma |
Bevacizumab-adcd |
Celltrion |
U.S. biosimilar |
| Avzivi |
Bevacizumab-tnjn |
Bio-Thera Solutions, marketed by Bio-Thera and partners |
U.S. biosimilar |
The competitive group includes large multinational manufacturers and specialized biosimilar developers. Amgen had an early-mover advantage with Mvasi. Pfizer followed with Zirabev and gained value from its hospital and oncology commercial infrastructure. Celltrion and other entrants increased tender and account-level pricing pressure.
How does Zirabev compare with Mvasi and Avastin?
| Commercial factor |
Avastin |
Mvasi |
Zirabev |
| Role |
Reference biologic |
Biosimilar |
Biosimilar |
| Sponsor |
Genentech/Roche |
Amgen |
Pfizer |
| FDA approval |
2004 |
2017 |
2019 |
| Launch position |
Established standard of care |
First U.S. entrant |
Early second-wave entrant |
| Interchangeability |
Not applicable as reference product |
Depends on FDA designation |
Not initially interchangeable |
| Primary advantage |
Clinical familiarity and historical use |
Early market access |
Pfizer scale and oncology contracting |
| Main risk |
Biosimilar erosion |
Multi-biosimilar price competition |
Share fragmentation and price compression |
Avastin retains clinical familiarity and may remain preferred by some physicians or institutions. Biosimilars gain leverage when hospitals use formulary substitution, preferred-product contracts, or value-based purchasing. The product selected can differ by health system, payer, group purchasing organization, and site of care.
What is the market outlook for bevacizumab biosimilars?
The market is mature relative to newer oncology biosimilar categories. Bevacizumab has high treatment volume, established clinical use, and substantial cumulative spending. These characteristics attract multiple suppliers but also accelerate price competition.
The market dynamics are shaped by five factors:
- Hospital procurement. Large health systems and group purchasing organizations can negotiate discounts across oncology portfolios.
- Site of care. Buy-and-bill economics influence provider choice because acquisition cost and reimbursement spread affect treatment economics.
- Payer policies. Preferred biosimilar placement can move utilization without requiring automatic pharmacy substitution.
- Physician confidence. FDA biosimilarity determinations reduce clinical uncertainty, but switching policies remain account-specific.
- Supply reliability. Oncology providers value continuity of supply, particularly when products are administered in high-volume infusion centers.
Biosimilar uptake in the United States has generally been faster in physician-administered oncology products than in many self-administered biologics. Bevacizumab’s hospital-administered format supports institutional purchasing decisions, although it also makes contracting and reimbursement more important than retail pharmacy substitution.
What is the financial trajectory for bevacizumab-bvzr?
Pfizer does not disclose Zirabev net sales as a separate line item in its public financial reporting. Pfizer reports broader business segments and product categories, while biosimilar revenue may be grouped with other products or included in a broader oncology portfolio. A precise product-level revenue trajectory is therefore not available from audited company disclosures.
The financial profile can be assessed through the following phases:
2019-2020: launch and early adoption
Zirabev received FDA approval in 2019 and launched in January 2020. Early revenue benefited from:
- entry before the full group of later bevacizumab biosimilars;
- Pfizer’s global hospital and oncology infrastructure;
- Avastin’s large established treatment base;
- provider interest in lower-cost alternatives.
The COVID-19 pandemic disrupted hospital activity and oncology treatment volumes in 2020, creating a temporary offset to biosimilar launch momentum.
2021-2023: portfolio scaling and competition
During this period, the product moved from launch expansion to account retention. Competition intensified as Mvasi established itself and additional products reached the U.S. market. Net price became more important than gross sales growth.
Revenue performance likely depended on:
- share of new starts;
- conversion of Avastin patients;
- retention under institutional contracts;
- average selling price after rebates;
- European tender outcomes; and
- manufacturing utilization.
2024 onward: mature, price-sensitive market
Zirabev’s future revenue is more likely to reflect share and price than market expansion. The underlying bevacizumab market can grow modestly with cancer incidence, treatment duration, and expanded use, but biosimilar competition transfers value from manufacturers to payers and providers.
A reasonable commercial trajectory is:
| Period |
Financial driver |
Expected effect |
| Launch phase |
Early biosimilar adoption |
Volume growth |
| Multi-competitor phase |
Contracting and share competition |
Lower net price |
| Mature phase |
Stable demand and replacement sales |
Flat-to-declining revenue unless share gains offset erosion |
What revenue exposure does Pfizer have to Zirabev?
Zirabev is strategically important to Pfizer’s biosimilar and oncology portfolio, but it is unlikely to be material to Pfizer’s total corporate revenue on a standalone basis. Pfizer’s annual revenue is measured in tens of billions of dollars, while the company does not identify Zirabev as an individual billion-dollar product in its public reporting.
The product can still have meaningful business value because it:
- uses Pfizer’s manufacturing and commercial infrastructure;
- supports hospital and oncology account relationships;
- contributes recurring revenue after launch costs;
- strengthens Pfizer’s biosimilar portfolio; and
- creates cross-selling opportunities with other oncology products.
The main financial risk is margin compression. Biosimilars can generate high initial revenue growth followed by declining net prices as competitors increase rebate intensity.
How strong is the patent estate for bevacizumab-bvzr?
Zirabev has a moderate commercial protection profile and a weak long-term exclusivity profile. Its strengths are regulatory approval, manufacturing complexity, Pfizer’s scale, and clinical familiarity with bevacizumab. Its weaknesses are the absence of a conventional standalone patent moat, multiple approved competitors, and limited automatic substitution rights.
| Strength factor |
Assessment |
| Regulatory barrier |
High relative to generics |
| Manufacturing barrier |
High |
| Core molecule exclusivity |
Limited for the biosimilar |
| Orange Book protection |
Not applicable as the primary framework |
| Competitor count |
Increasing |
| Pricing power |
Low to moderate |
| Hospital contracting importance |
High |
| Long-term margin protection |
Limited |
What generic or biosimilar launch risks exist?
The principal launch risk is additional biosimilar competition rather than an ANDA generic. A future entrant can pressure Zirabev through lower pricing, preferred contracts, or an interchangeability designation if granted.
Key risk channels include:
- new FDA-approved bevacizumab biosimilars;
- payer mandates favoring a competitor;
- hospital conversion programs;
- manufacturing supply interruptions;
- lower-cost international suppliers;
- changes to Medicare reimbursement;
- reduced provider spread; and
- competitive bundling with other oncology biosimilars.
A biosimilar does not need to be interchangeable to win substantial institutional share. Hospitals can adopt a preferred product through formulary, contracting, or physician-policy decisions.
What licensing deals and manufacturing barriers matter?
Pfizer’s biosimilar business depends on global development, manufacturing, and commercial capabilities. Biosimilar licensing arrangements can divide rights by geography, indication, or commercial channel. Public filings do not establish a single licensing transaction that determines Zirabev’s worldwide economics.
Manufacturing remains a meaningful barrier. Bevacizumab production requires mammalian-cell culture, purification, aseptic fill-finish, validated analytical methods, and cold-chain distribution. These requirements reduce the number of credible entrants compared with conventional generic injectables.
Manufacturing complexity does not prevent price erosion once several suppliers qualify with regulators. It mainly limits the number of firms capable of entering and reduces the risk of immediate commodity-style oversupply.
What is the generic launch scenario for Zirabev?
The most likely U.S. launch scenario is continued multi-biosimilar competition with gradual net-price erosion. A sudden substitution event is less likely because Zirabev is not automatically interchangeable with Avastin based solely on its original biosimilar approval.
Three scenarios are commercially relevant:
| Scenario |
Market outcome |
Zirabev impact |
| Base case |
Several biosimilars share the market; discounts deepen gradually |
Stable or declining revenue |
| Upside case |
Pfizer wins preferred contracts and preserves supply reliability |
Share gains offset price erosion |
| Downside case |
A competitor gains preferred payer and hospital status |
Rapid share and margin loss |
What is the geographic coverage of Zirabev?
Zirabev has regulatory and commercial presence in the United States and Europe, with broader availability depending on country-level approval, reimbursement, and procurement. European markets are fragmented by national health systems and tenders. A product can hold strong share in one country and weak share in another.
The United States remains commercially important because of its oncology buy-and-bill structure and high drug spending. Europe can provide volume but often imposes greater tender-based price pressure.
Key Takeaways
- Bevacizumab-bvzr is Pfizer’s Zirabev, a biosimilar to Avastin.
- FDA approval occurred on June 27, 2019; U.S. launch followed in January 2020.
- Zirabev does not have a conventional Orange Book patent-expiration date.
- Biosimilar patent disputes are governed through the BPCIA framework rather than standard Paragraph IV ANDA litigation.
- Mvasi, Alymsys, Vegzelma, and Avzivi increase U.S. competitive pressure.
- Pfizer does not publicly disclose Zirabev revenue separately.
- The product’s financial trajectory is likely volume-stable but price-sensitive, with net revenue exposed to contracting and biosimilar competition.
- Manufacturing complexity creates entry barriers but does not provide durable pricing power after multiple biosimilars launch.
- The principal commercial assets are Pfizer’s scale, hospital access, supply reliability, and contracting capability.
- The principal risks are share fragmentation, rebate competition, reimbursement changes, and additional biosimilar entry.
FAQs
Is bevacizumab-bvzr interchangeable with Avastin?
Zirabev was approved as biosimilar to Avastin, but its original FDA approval did not establish automatic interchangeability. Substitution depends on FDA designation, state law, payer policy, and institutional practice.
Does Zirabev have a Paragraph IV patent challenge?
Not in the conventional ANDA sense. Zirabev was approved through the BPCIA biosimilar pathway, which uses patent-information exchange and related litigation procedures rather than a standard Paragraph IV certification.
Who owns Zirabev?
Pfizer markets Zirabev. The reference product Avastin is associated with Genentech and Roche.
Is Zirabev cheaper than Avastin?
Zirabev is intended to create lower-cost competition, but the realized discount varies by hospital contract, payer, provider acquisition terms, rebates, and reimbursement policy.
Are biosimilars reducing Avastin revenue?
Yes. Avastin faces erosion from multiple FDA-approved bevacizumab biosimilars. The magnitude varies by indication, provider, payer, geography, and contracting arrangement.
References
- European Medicines Agency. (2019). Zirabev: EPAR product information. https://www.ema.europa.eu
- Pfizer Inc. (2024). Annual report 2023. https://www.pfizer.com/investors/financial-information/annual-reports
- U.S. Food and Drug Administration. (2019). FDA approves biosimilar to Avastin. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024). Biosimilar product information. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars
- U.S. Food and Drug Administration. (2024). Avastin prescribing information. https://www.accessdata.fda.gov/drugsatfda
- Congress of the United States. (2010). Biologics Price Competition and Innovation Act of 2009. Public Law 111-148.
